Alkem Laboratories Ltd. · NSE:ALKEM
Alkem Laboratories — Q4 FY2024 Earnings Presentation
23 slides from Alkem Laboratories's earnings presentation, May 29, 2024
Slide 1: Exchange filing cover letter for Q4FY24 results
29th May, 2024 To, The Corporate Relationship Department National Stock Exchange of India Limited BSE Limited Exchange Plaza, Phiroze Jeejeebhoy Towers, Bandra Kurla Complex, Dalal Street, Bandra East, Mumbai 400 001. Mumbai 400 051. Scrip Code: 539523 Scrip Symbol: ALKEM Sub: Press Release and Anal
Slide 2: Alkem reports Q4FY24 and FY24 results
Press Release Alkem reports Q4FY24 and FY24 results Mumbai, May 29, 2024: Alkem Laboratories Ltd. (Alkem) today announced its standalone and consolidated financial results for the fourth quarter and the full year ended March 31, 2024. These results were taken on record by the Board of Directors at i
Slide 3: CEO commentary and operational highlights
Commenting on the FY24 results, Dr Vikas Gupta, CEO, Alkem said "Our focus has been to improve EBIDTA margin during the year, on the back of benefits through various cost -control initiatives being implemented along with favourable API prices. Continuing our trend of improved performance, Q4FY24 bui
Slide 4: Key performance highlights of therapeutic segments in Q4FY24 and FY24
Key performance highlights of therapeutic segments in Q4FY24 and FY24 Q4FY24 FY24 Key Therapy segment Alkem YoY change in YoY YoY Alkem YoY change in YoY YoY Rank Rank* (Alkem) (IPM) Rank Rank* (Alkem) (IPM) ANTI DIABETIC 15 Unchanged 17.9% 6.9% 15 Improved by 1 21.6% 6.0% ANTI-INFECTIVES 1 Unchange
Slide 5: Update on USFDA Inspections
Update on USFDA Inspections Facility Capability Last inspection Status post last inspection Daman (India) Formulations August 2019 EIR Received in Oct 2019. Received Form 483 with ten observations. Baddi (India) Formulations March 2024 USFDA inspection was done between 19-27 March 2024. Response is
Slide 6: Q4FY24 & FY24 Conference Call details
Q4FY24 & FY24 Conference Call at 5 pm IST, May 29, 2024 Alkem will organize a conference call for investors and analysts on Wednesday, May 29, 2024 from 5:00pm to 6:00pm IST to discuss its Q4FY24 & FY24 financial results. Alkem Laboratories Ltd. will be represented on the call by: Dr. Vikas Gupta –
Slide 7: Investor Presentation Q4FY24 & FY24
Investor Presentation Q4FY24 & FY24 May 29, 2024
Slide 8: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and
Slide 9: Key Highlights of FY24
Key Highlights of FY24 • Total Revenue from Operations was ₹ 126,676 million, year-on-year growth of 9.2%. • India sales were ₹ 84,337 million, year-on-year growth of 5.4%. • International sales were ₹ 40,024 million, year-on-year growth of 16.4%. • Earnings before Interest, Tax, Depreciation and Am
Slide 10: Key Financial Highlights – FY24 (Consolidated)
Key Financial Highlights – FY24 (Consolidated) All figures in ₹ Mn Revenue from Operations India sales 84,336 80,011 126,676 115,993 FY23 FY24 International sales 40,024 34,393 FY23 FY24 FY23 FY24
Slide 11: Key Financial Highlights – FY24 (Consolidated)
Key Financial Highlights – FY24 (Consolidated) All figures in ₹ Mn Gross Profit and Gross Margin EBITDA and EBITDA Margin PBT (before exceptional item) 22,455 21,446 77,300 66,924 16,095 14,078 57.7% 61.0% 13.9% 17.7% FY23 FY24 FY23 FY24 FY23 FY24 PAT (after Minority Interest) PBT (after exceptional
Slide 12: Secondary Sales Performance FY24
Secondary Sales Performance Mixed performance across all major therapeutic segments in FY24 1 3 3 2 Market rank Acute Therapies Anti-infectives Gastro-intestinal Pain/ Analgesics Vitamins/ Minerals / Nutrients 9.3% 9.0% 8.1% 7.2% 7.3% 4.7% 5.3% 2.0% Alkem sales growth YoY1,2 Indian pharma industry s
Slide 13: Key Highlights of Q4FY24
Key Highlights of Q4FY24 • Total Revenue from Operations were ₹ 29,358 million, year-on-year growth of 1.1%. • India sales were ₹ 19,724 million, year-on-year de-growth of 1.9%. • International sales were ₹ 9,096 million, year-on-year growth of 6.1%. • Earnings before Interest, Tax, Depreciation and
Slide 14: Key Financial Highlights – Q4FY24 (Consolidated)
Key Financial Highlights – Q4FY24 (Consolidated) All figures in ₹ Mn Revenue from Operations India sales 20,113 19,724 29,026 29,358 Q4FY23 Q4FY24 International sales 8,570 9,096 Q4FY23 Q4FY24 Q4FY23 Q4FY24
Slide 15: Key Financial Highlights – Q4FY24 (Consolidated)
Key Financial Highlights – Q4FY24 (Consolidated) All figures in ₹ Mn Gross Profit and Gross Margin EBITDA and EBITDA Margin PBT (before exceptional item) 3,799 18,824 16,471 4,020 3,146 3,533 56.7% 62.3% 12.2% 13.7% Q4FY23 Q4FY24 Q4FY23 Q4FY24 Q4FY23 Q4FY24 PAT (after Minority Interest) PBT (after e
Slide 16: Secondary Sales Performance Q4FY24
Secondary Sales Performance Mixed performance across all major therapeutic segments in Q4FY24 +1 1 3 3 2 Market rank Acute Therapies Anti-infectives Gastro-intestinal Pain/ Analgesics Vitamins/ Minerals / Nutrients 13.0% 5.4% 5.8% 6.6% 2.3% 1.7% -2.2% -6.4% Alkem sales growth YoY1,2 Indian pharma in
Slide 17: India Business Update
India Business Update Q4FY24 Sales of ₹ 19,724 million (1.9% YoY decline) • Contribution of domestic sales to total sales in Q4FY24 was 68.4% and for FY24 was 67.8%. • As per IQVIA, in Q4FY24, the Company’s secondary sales grew by 1.4% compared to IPM growth of 5.7% YoY and in FY24, the Company’s se
Slide 18: US Business Update
US Business Update Q4FY24 Sales of ₹ 6,241 million (5.5% YoY growth) • Overall contribution of US sales to total sales was 21.7% in Q4FY24 and in FY24 as well. • During Q4FY24, the US business grew by 5.5% and in FY24 it grew by 10.2%. • During Q4FY24, the Company has filed 4 ANDA and has received 2
Slide 19: Update on USFDA inspections
Update on USFDA inspections Facility Inspection Date Regulatory Status Received Form 483 with ten observations for Baddi (India) Mar-24 USFDA inspection done between 19-27 Mar 2024. Response submitted to USFDA. Daman (India) Aug-19 EIR Received in Oct 2019 Taloja R&D (India) Oct-22 No observation An
Slide 20: Other International Business Update
Other International Business Update Q4FY24 Sales of ₹ 2,855 million (7.6% YoY growth) • Other International Market sales contributed 10% to total sales in Q4FY24 as well as in FY24. • For FY24,our Non-US business has contributed significantly amidst launch of limited competition products in our key
Slide 21: Shareholding Pattern as on March 31, 2024
Shareholding Pattern as on March 31, 2024 Non-Institution BSE Ticker 539523 18.86% NSE Symbol ALKEM Promoter & Promoter Group Shares Outstanding (Mn) 119.55 Institution 56.74% MCap (Rs in Mn)* 590,816 24.40% Free Float Mcap (Rs in Mn) 255,587 Industry Pharmaceuticals Institution – Mutual Funds, Alte
Slide 22: Key Financial Highlights – Q4FY24 & FY24 (Consolidated)
Key Financial Highlights – Q4FY24 & FY24(Consolidated) All figures in ₹ Mn Particulars Q4FY24 Q4FY23 YoY growth FY24 FY23 YoY growth Revenue from Operations 29,358 29,026 1.1% 126,676 115,993 9.2% Gross Profit 18,284 16,471 11.0% 77,300 66,924 15.5% Gross Profit Margin 62.3% 56.7% 61.0% 57.7% EBITDA
Slide 23: Thank You
Thank You For any queries, contact: Purvi Shah - Head of Investor Relations Mobile: +91 84337 00890 Tel: +91 22 3982 9999 Ext: 9447 E-mail: purvi.shah@alkem.com